Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD45RA+ Depletion in Allogeneic HSCT for GVHD Prevention
NCT00914940Phase 2Terminated
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Dec 2009
- Primary completion
- Dec 2019
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CD45RA-depleted peripheral blood stem cells in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Fred Hutchinson Cancer Center. Primary endpoints: Probability of grades II-IV acute graft-vs-host disease at 360 days and Probability of graft failure at 5 years. Started Dec 2009; status: terminated.
02
Drugs
CD45RA-depleted peripheral blood stem cells
03
Conditions
acute lymphoblastic leukemia (ALL)acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00914940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00914940.